{"transactions":[{"id":765941,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-05-22T20:03:42.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest in full on the anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.42,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001683168-26-004243","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826004243/ownership.xml","form_type":"4"}},{"id":915820,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-06T21:55:20.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":103000,"source":{"system":"sec-edgar","filing":"0001193125-26-041344","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526041344/ownership.xml","form_type":"4"}},{"id":946452,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7256,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7256},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946451,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1328,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1328},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946450,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13340,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13340},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946449,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":75.5,"underlying":"Common Stock","underlying_shares":7467},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946448,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":497,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":75.5,"underlying":"Common Stock","underlying_shares":497},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946447,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":364,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":31.5,"underlying":"Common Stock","underlying_shares":364},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946446,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27878,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":33,"underlying":"Common Stock","underlying_shares":27878},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946445,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12121,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":33,"underlying":"Common Stock","underlying_shares":12121},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946444,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":179,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":85.5,"underlying":"Common Stock","underlying_shares":179},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946443,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":734,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":216,"underlying":"Common Stock","underlying_shares":734},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946442,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":135,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":106.25,"underlying":"Common Stock","underlying_shares":135},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946441,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":90.5,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946440,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":407,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":161,"underlying":"Common Stock","underlying_shares":407},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946439,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1002,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":372.5,"underlying":"Common Stock","underlying_shares":1002},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946438,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":527.25,"underlying":"Common Stock","underlying_shares":99},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946437,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1923,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":214.25,"underlying":"Common Stock","underlying_shares":1923},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946436,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26713,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."}],"balance_after":0,"derivative":{"exercise_price":16.0125,"underlying":"Common Stock","underlying_shares":26713},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946435,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5938,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."}],"balance_after":0,"derivative":{"exercise_price":16.0125,"underlying":"Common Stock","underlying_shares":5938},"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":946434,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-01-06T21:47:18.000Z","date":"2026-01-06","kind":"other","planned":false,"acquired":false,"shares":9573,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-001376","document":"tm261736-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001376/tm261736-6_4seq1.xml","form_type":"4"}},{"id":1040283,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-09-15T20:26:13.000Z","date":"2025-09-11","kind":"exercise","planned":true,"acquired":false,"shares":6670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the total number of RSUs granted vested on September 11, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"25% of the total number of RSUs granted vested on September 11, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025."}],"balance_after":13340,"derivative":{"underlying":"Common Stock","underlying_shares":20010},"source":{"system":"sec-edgar","filing":"0001104659-25-090026","document":"tm2526132-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925090026/tm2526132-1_4seq1.xml","form_type":"4"}},{"id":1040282,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2025-09-15T20:26:13.000Z","date":"2025-09-12","kind":"sale","planned":true,"acquired":false,"shares":2012,"price":7.31,"value":14707.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic \"sell to cover\" transaction that did not represent a discretionary trade by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.22 to $7.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025."}],"balance_after":9572,"source":{"system":"sec-edgar","filing":"0001104659-25-090026","document":"tm2526132-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925090026/tm2526132-1_4seq1.xml","form_type":"4"}},{"id":1040281,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2025-09-15T20:26:13.000Z","date":"2025-09-11","kind":"exercise","planned":true,"acquired":true,"shares":6670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on September 11, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025."}],"balance_after":11584,"source":{"system":"sec-edgar","filing":"0001104659-25-090026","document":"tm2526132-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925090026/tm2526132-1_4seq1.xml","form_type":"4"}},{"id":1142090,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T20:02:03.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":8.99,"value":44950.0,"ownership":{"direct":true},"balance_after":79000,"source":{"system":"sec-edgar","filing":"0000950170-25-074297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025074297/ownership.xml","form_type":"4"}},{"id":1278476,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T21:34:03.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":74000,"source":{"system":"sec-edgar","filing":"0000950170-25-016351","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025016351/ownership.xml","form_type":"4"}},{"id":1299998,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-01-18T00:21:15.000Z","date":"2025-01-15","kind":"grant","planned":true,"acquired":true,"shares":181400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."}],"balance_after":181400,"derivative":{"underlying":"Common Stock","underlying_shares":181400},"source":{"system":"sec-edgar","filing":"0001104659-25-004593","document":"tm253733-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004593/tm253733-4_4seq1.xml","form_type":"4"}},{"id":1299997,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-18T00:21:15.000Z","date":"2025-01-15","kind":"grant","planned":true,"acquired":true,"shares":816300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option shall vest in equal quarterly installments over four years from the date of grant."}],"balance_after":816300,"derivative":{"exercise_price":0.64,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":816300},"source":{"system":"sec-edgar","filing":"0001104659-25-004593","document":"tm253733-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004593/tm253733-4_4seq1.xml","form_type":"4"}},{"id":1299996,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-01-18T00:21:15.000Z","date":"2025-01-15","kind":"exercise","planned":true,"acquired":false,"shares":11062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years."}],"balance_after":33188,"derivative":{"underlying":"Common Stock","underlying_shares":11062},"source":{"system":"sec-edgar","filing":"0001104659-25-004593","document":"tm253733-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004593/tm253733-4_4seq1.xml","form_type":"4"}},{"id":1299995,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2025-01-18T00:21:15.000Z","date":"2025-01-16","kind":"sale","planned":true,"acquired":false,"shares":4514,"price":0.58,"value":2618.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic \"sell to cover\" transaction that did not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":122875,"source":{"system":"sec-edgar","filing":"0001104659-25-004593","document":"tm253733-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004593/tm253733-4_4seq1.xml","form_type":"4"}},{"id":1299994,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2025-01-18T00:21:15.000Z","date":"2025-01-15","kind":"exercise","planned":true,"acquired":true,"shares":11062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on January 15, 2024."}],"balance_after":127389,"source":{"system":"sec-edgar","filing":"0001104659-25-004593","document":"tm253733-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004593/tm253733-4_4seq1.xml","form_type":"4"}},{"id":1407608,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-09-13T21:08:39.000Z","date":"2024-09-11","kind":"exercise","planned":true,"acquired":false,"shares":166750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the RSUs granted vested on September 11, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"25% of the RSUs granted vested on September 11, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years."}],"balance_after":500250,"derivative":{"underlying":"Common Stock","underlying_shares":166750},"source":{"system":"sec-edgar","filing":"0001104659-24-099855","document":"tm2424033-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924099855/tm2424033-2_4seq1.xml","form_type":"4"}},{"id":1407607,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2024-09-13T21:08:39.000Z","date":"2024-09-12","kind":"sale","planned":true,"acquired":false,"shares":50423,"price":1.76,"value":88744.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic \"sell to cover\" transaction that did not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.735 to $1.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":116327,"source":{"system":"sec-edgar","filing":"0001104659-24-099855","document":"tm2424033-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924099855/tm2424033-2_4seq1.xml","form_type":"4"}},{"id":1407606,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2024-09-13T21:08:39.000Z","date":"2024-09-11","kind":"exercise","planned":true,"acquired":true,"shares":166750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on September 11, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 12, 2023, the Reporting Person filed a Form 4 reporting the award of a RSU award representing the right to receive 14,467 shares of common stock of the Issuer on June 8, 2023. Such RSU award was subsequently rescinded in connection with the Reporting Person's appointment as president and chief executive officer effective in September 2023 and as a result was cancelled for no value. The amount of securities beneficially owned reported in this Form 4 reflects an adjustment in the number of shares held by the Reporting Person, reflecting the cancellation of the June 8, 2023 RSU award for no value."}],"balance_after":166750,"source":{"system":"sec-edgar","filing":"0001104659-24-099855","document":"tm2424033-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924099855/tm2424033-2_4seq1.xml","form_type":"4"}},{"id":1651295,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T21:04:51.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":49000,"source":{"system":"sec-edgar","filing":"0001562180-24-001220","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218024001220/primarydocument.xml","form_type":"4"}},{"id":1677745,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-01-17T22:19:30.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":44250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."}],"balance_after":44250,"derivative":{"underlying":"Common Stock","underlying_shares":44250},"source":{"system":"sec-edgar","filing":"0001104659-24-004545","document":"tm243529-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924004545/tm243529-4_4seq1.xml","form_type":"4"}},{"id":1677744,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-17T22:19:30.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":199125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over four years from the date of grant."}],"balance_after":199125,"derivative":{"exercise_price":3.02,"expiration_date":"2034-01-14","underlying":"Common Stock","underlying_shares":199125},"source":{"system":"sec-edgar","filing":"0001104659-24-004545","document":"tm243529-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924004545/tm243529-4_4seq1.xml","form_type":"4"}},{"id":1765224,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-04T20:31:52.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":9102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for non-employee director services in the form of stock options rather than cash.  The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $9,557.69 for service as a non-employee director between July 1, 2023 and September 10, 2023 in the quarter ended September 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":9102,"derivative":{"exercise_price":1.26,"expiration_date":"2033-10-01","underlying":"Common Stock","underlying_shares":9102},"source":{"system":"sec-edgar","filing":"0001104659-23-106843","document":"tm2327613-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923106843/tm2327613-5_4seq1.xml","form_type":"4"}},{"id":1781980,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted stock unit","published_at":"2023-09-13T20:01:38.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":667000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs shall vest in equal annual installments over four years from the date of grant, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs shall vest in equal annual installments over four years from the date of grant, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":667000,"derivative":{"underlying":"Common Stock","underlying_shares":667000},"source":{"system":"sec-edgar","filing":"0001104659-23-100441","document":"tm2326002-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923100441/tm2326002-1_4seq1.xml","form_type":"4"}},{"id":1781979,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock option (right to buy)","published_at":"2023-09-13T20:01:38.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on the first anniversary of the grant, and the remainder shall vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":1000000,"derivative":{"exercise_price":1.32,"expiration_date":"2033-09-10","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001104659-23-100441","document":"tm2326002-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923100441/tm2326002-1_4seq1.xml","form_type":"4"}},{"id":1801531,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND HEAD OF R&D"}}],"security":"Stock Option (right to buy)","published_at":"2023-08-19T00:30:10.000Z","date":"2023-08-16","kind":"grant","planned":false,"acquired":true,"shares":136500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date."}],"balance_after":136500,"derivative":{"exercise_price":2.785,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":136500},"source":{"system":"sec-edgar","filing":"0001415889-23-012415","document":"form4-08182023_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653276/000141588923012415/form4-08182023_080801.xml","form_type":"4"}},{"id":1833759,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-07-06T20:23:05.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":4477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash.  The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $12,250 for the quarter ended June 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":4477,"derivative":{"exercise_price":3.42,"expiration_date":"2033-07-02","underlying":"Common Stock","underlying_shares":4477},"source":{"system":"sec-edgar","filing":"0001104659-23-078752","document":"tm2320657-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923078752/tm2320657-3_4seq1.xml","form_type":"4"}},{"id":1858671,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:16:57.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":18355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":18355,"derivative":{"exercise_price":8.64,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":18355},"source":{"system":"sec-edgar","filing":"0001104659-23-070362","document":"tm2318463-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070362/tm2318463-4_4seq1.xml","form_type":"4"}},{"id":1858670,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:16:57.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":14467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  Each RSU represents the contingent right to receive one share of Common Stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":14467,"source":{"system":"sec-edgar","filing":"0001104659-23-070362","document":"tm2318463-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070362/tm2318463-4_4seq1.xml","form_type":"4"}},{"id":1924927,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-05T21:15:12.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":3375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $11,000 for the quarter ended March 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant"}],"balance_after":3375,"derivative":{"exercise_price":4.25,"expiration_date":"2033-04-02","underlying":"Common Stock","underlying_shares":3375},"source":{"system":"sec-edgar","filing":"0001104659-23-042244","document":"tm2311858-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923042244/tm2311858-4_4seq1.xml","form_type":"4"}},{"id":2032316,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T21:56:06.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-23-000946","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023000946/primarydocument.xml","form_type":"4"}},{"id":2065538,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND HEAD OF R&D"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-04T21:11:57.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":136500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on January 1, 2023 and shall vest on February 1, 2023 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until January 1, 2027."}],"balance_after":136500,"derivative":{"exercise_price":2.69,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":136500},"source":{"system":"sec-edgar","filing":"0001415889-23-000289","document":"form4-01042023_090139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653276/000141588923000289/form4-01042023_090139.xml","form_type":"4"}},{"id":2222705,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND HEAD OF R&D"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-23T23:30:17.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on June 15, 2022 and shall vest on July 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until June 1, 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.28,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-22-006908","document":"form4a-06232022_070602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653276/000141588922006908/form4a-06232022_070602.xml","form_type":"4/A","original_submission_date":"2022-06-17"}},{"id":2226575,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND HEAD OF R&D"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:31:18.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on June 15, 2022 and will vest in equal monthly installments until June 15, 2026, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.28,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-22-006747","document":"form4-06172022_040644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653276/000141588922006747/form4-06172022_040644.xml","form_type":"4"}},{"id":2235784,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T20:18:17.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":3.62,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-22-070138","document":"tm2218135-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922070138/tm2218135-2_4seq1.xml","form_type":"4"}},{"id":2373961,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT OF R&D AND CMO"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-24T22:30:27.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on February 22, 2022 and shall vest on March 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until February 1, 2026."}],"balance_after":65000,"derivative":{"exercise_price":12.66,"expiration_date":"2032-02-21","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001415889-22-001792","document":"form4-02242022_050208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653276/000141588922001792/form4-02242022_050208.xml","form_type":"4"}},{"id":2413088,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-03T22:28:48.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001562180-22-001069","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022001069/primarydocument.xml","form_type":"4"}},{"id":2443722,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T22:05:41.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2022."}],"balance_after":10185,"derivative":{"exercise_price":6.44,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10185},"source":{"system":"sec-edgar","filing":"0001104659-22-001558","document":"tm221771-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922001558/tm221771-5_4seq1.xml","form_type":"4"}},{"id":2535370,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R&D and CMO"}}],"security":"Stock Option (right to buy)","published_at":"2021-10-25T21:17:40.000Z","date":"2021-10-21","kind":"grant","acquired":true,"shares":157058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on October 21, 2021 and will begin to vest on November 1, 2021 and continue to vest in equal monthly installments thereafter until October 1, 2025."}],"balance_after":157058,"derivative":{"exercise_price":16,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":157058},"source":{"system":"sec-edgar","filing":"0001104659-21-129570","document":"tm2130646-21_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653276/000110465921129570/tm2130646-21_4seq1.xml","form_type":"4"}},{"id":2565248,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2021-09-17T20:32:54.000Z","date":"2021-09-15","kind":"grant","acquired":true,"shares":35000,"price":19.36,"value":677600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over a three-year period."}],"balance_after":35000,"derivative":{"exercise_price":19.36,"expiration_date":"2031-09-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001562180-21-006002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021006002/primarydocument.xml","form_type":"4"}},{"id":2668157,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T22:01:10.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":25050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2022 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":25050,"derivative":{"exercise_price":14.9,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":25050},"source":{"system":"sec-edgar","filing":"0001104659-21-081606","document":"tm2119714-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921081606/tm2119714-1_4seq1.xml","form_type":"4"}},{"id":2902203,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-21T00:02:39.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":2490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2021."}],"balance_after":2490,"derivative":{"exercise_price":21.09,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":2490},"source":{"system":"sec-edgar","filing":"0001104659-21-005944","document":"tm211948-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921005944/tm211948-5_4seq1.xml","form_type":"4"}},{"id":3100800,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy","published_at":"2020-06-24T21:07:01.000Z","date":"2020-04-13","kind":"grant","acquired":true,"shares":48096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments over three years from the date of the grant."}],"balance_after":48096,"derivative":{"exercise_price":8.57,"expiration_date":"2030-04-13","underlying":"Common Stock","underlying_shares":48096},"source":{"system":"sec-edgar","filing":"0001104659-20-076483","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465920076483/a4.xml","form_type":"4"}},{"id":3690682,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-22T09:57:01.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":39942,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":55.84,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":39942},"source":{"system":"sec-edgar","filing":"0001123292-19-000168","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000168/edgar.xml","form_type":"4"}},{"id":3690681,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-22T09:57:01.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":10782,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":178.95,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":10782},"source":{"system":"sec-edgar","filing":"0001123292-19-000168","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000168/edgar.xml","form_type":"4"}},{"id":3690680,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-22T09:57:01.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":43.39,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001123292-19-000168","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000168/edgar.xml","form_type":"4"}},{"id":3690679,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-22T09:57:01.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":55.14,"expiration_date":"2025-09-21","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001123292-19-000168","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000168/edgar.xml","form_type":"4"}},{"id":3690678,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-22T09:57:01.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":22727,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22727},"source":{"system":"sec-edgar","filing":"0001123292-19-000168","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000168/edgar.xml","form_type":"4"}},{"id":3690677,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-22T09:57:01.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":4447,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4447},"source":{"system":"sec-edgar","filing":"0001123292-19-000168","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000168/edgar.xml","form_type":"4"}},{"id":3690676,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-22T09:57:01.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":8750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001123292-19-000168","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000168/edgar.xml","form_type":"4"}},{"id":3690675,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-22T09:57:01.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001123292-19-000168","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000168/edgar.xml","form_type":"4"}},{"id":3690674,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-01-22T09:57:01.000Z","date":"2019-01-22","kind":"other","acquired":false,"shares":12206,"price":75,"value":915450.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation (\"Purchaser\") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales (\"Parent\"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation (\"TESARO\"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the \"Merger Agreement\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001123292-19-000168","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000168/edgar.xml","form_type":"4"}},{"id":3808267,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2018-09-25T18:00:18.000Z","date":"2018-09-21","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on September 21, 2015, and vest in four equal annual installments beginning September 21, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on September 21, 2015, and vest in four equal annual installments beginning September 21, 2016."}],"balance_after":1250,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-18-058485","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918058485/a4.xml","form_type":"4"}},{"id":3808266,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-25T18:00:18.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":371,"price":37.63,"value":13960.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and a 10b5-1 trading plan entered into by the Reporting Person and was made in order to pay the tax liability arising from the vesting of the restricted stock units."}],"balance_after":12206,"source":{"system":"sec-edgar","filing":"0001104659-18-058485","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918058485/a4.xml","form_type":"4"}},{"id":3808265,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-25T18:00:18.000Z","date":"2018-09-21","kind":"exercise","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12577,"source":{"system":"sec-edgar","filing":"0001104659-18-058485","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918058485/a4.xml","form_type":"4"}},{"id":4015202,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-03-05T17:25:55.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":39942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in 48 equal monthly installments beginning on April 1, 2018."}],"balance_after":39942,"derivative":{"exercise_price":55.84,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":39942},"source":{"system":"sec-edgar","filing":"0001104659-18-014884","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918014884/a4.xml","form_type":"4"}},{"id":4015201,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-05T17:25:55.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":22727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest in four equal annual installments beginning on March 1, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vest in four equal annual installments beginning on March 1, 2019."}],"balance_after":22727,"derivative":{"underlying":"Common Stock","underlying_shares":22727},"source":{"system":"sec-edgar","filing":"0001104659-18-014884","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918014884/a4.xml","form_type":"4"}},{"id":4015200,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-05T17:25:55.000Z","date":"2018-03-01","kind":"exercise","acquired":false,"shares":1483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were granted on March 1, 2017, and the remaining RSUs vest in three equal annual installments on each of March 1, 2019, 2020 and 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs were granted on March 1, 2017, and the remaining RSUs vest in three equal annual installments on each of March 1, 2019, 2020 and 2021."}],"balance_after":4447,"derivative":{"underlying":"Common Stock","underlying_shares":1483},"source":{"system":"sec-edgar","filing":"0001104659-18-014884","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918014884/a4.xml","form_type":"4"}},{"id":4015199,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-05T17:25:55.000Z","date":"2018-03-01","kind":"exercise","acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were granted on March 1, 2016, and the remaining RSUs vest in two equal annual installments on each of March 1, 2019 and 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were granted on March 1, 2016, and the remaining RSUs vest in two equal annual installments on each of March 1, 2019 and 2020."}],"balance_after":8750,"derivative":{"underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0001104659-18-014884","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918014884/a4.xml","form_type":"4"}},{"id":4015198,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T17:25:55.000Z","date":"2018-03-02","kind":"sale","acquired":false,"shares":1803,"price":54.86,"value":98912.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average. The shares were sold in multiple transactions at prices ranging from $54.30 to $54.86, inclusive. The reporting person undertakes to provide to TESARO, any security holder of TESARO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":11327,"source":{"system":"sec-edgar","filing":"0001104659-18-014884","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918014884/a4.xml","form_type":"4"}},{"id":4015197,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T17:25:55.000Z","date":"2018-03-01","kind":"exercise","acquired":true,"shares":1483,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13130,"source":{"system":"sec-edgar","filing":"0001104659-18-014884","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918014884/a4.xml","form_type":"4"}},{"id":4015196,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T17:25:55.000Z","date":"2018-03-01","kind":"exercise","acquired":true,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11647,"source":{"system":"sec-edgar","filing":"0001104659-18-014884","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918014884/a4.xml","form_type":"4"}},{"id":4141962,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-12-05T18:10:11.000Z","date":"2017-12-01","kind":"exercise","acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 27, 2016, the reporting person was granted 1,750 restricted stock units, all of which vested on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 27, 2016, the reporting person was granted 1,750 restricted stock units, all of which vested on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001104659-17-071945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917071945/a4.xml","form_type":"4"}},{"id":4141961,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-12-05T18:10:11.000Z","date":"2017-12-04","kind":"sale","acquired":false,"shares":829,"price":85.24,"value":70663.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and was made in order to pay the tax liability arising from the vesting of the restricted stock units."}],"balance_after":7272,"source":{"system":"sec-edgar","filing":"0001104659-17-071945","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917071945/a4.xml","form_type":"4"}},{"id":4141960,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-12-05T18:10:11.000Z","date":"2017-12-01","kind":"exercise","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 27, 2016, the reporting person was granted 1,750 restricted stock units, all of which vested on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."}],"balance_after":8101,"source":{"system":"sec-edgar","filing":"0001104659-17-071945","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917071945/a4.xml","form_type":"4"}},{"id":4156342,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-11-20T17:51:59.000Z","date":"2017-11-16","kind":"grant","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units fully vest on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units fully vest on December 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."}],"balance_after":1750,"derivative":{"underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001104659-17-069672","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917069672/a4.xml","form_type":"4"}},{"id":4202465,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-09-25T17:44:12.000Z","date":"2017-09-21","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On September 21, 2015, the reporting person was granted 5,000 restricted stock units, vesting in in four equal annual installments beginning September 21, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On September 21, 2015, the reporting person was granted 5,000 restricted stock units, vesting in in four equal annual installments beginning September 21, 2016."}],"balance_after":2500,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-17-058681","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917058681/a4.xml","form_type":"4"}},{"id":4202464,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-09-25T17:44:12.000Z","date":"2017-09-22","kind":"sale","acquired":false,"shares":592,"price":118.6,"value":70211.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of the restricted stock units."}],"balance_after":6351,"source":{"system":"sec-edgar","filing":"0001104659-17-058681","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917058681/a4.xml","form_type":"4"}},{"id":4202463,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-09-25T17:44:12.000Z","date":"2017-09-21","kind":"exercise","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."}],"balance_after":6943,"source":{"system":"sec-edgar","filing":"0001104659-17-058681","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917058681/a4.xml","form_type":"4"}},{"id":4361227,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Cheif Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-04-04T18:16:22.000Z","date":"2017-04-01","kind":"exercise","acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represented the right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units fully vested on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units fully vested on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001104659-17-021464","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917021464/a4.xml","form_type":"4"}},{"id":4361226,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Cheif Medical Officer"}}],"security":"Common Stock","published_at":"2017-04-04T18:16:22.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":829,"price":153.02,"value":126853.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and was made in order to pay the tax liability arising from the vesting of the restricted stock units."}],"balance_after":5693,"source":{"system":"sec-edgar","filing":"0001104659-17-021464","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917021464/a4.xml","form_type":"4"}},{"id":4361225,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Cheif Medical Officer"}}],"security":"Common Stock","published_at":"2017-04-04T18:16:22.000Z","date":"2017-04-01","kind":"exercise","acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units fully vested on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represented the right to receive one share of common stock."}],"balance_after":6522,"source":{"system":"sec-edgar","filing":"0001104659-17-021464","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917021464/a4.xml","form_type":"4"}},{"id":4369248,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-03-29T21:28:57.000Z","date":"2017-03-27","kind":"grant","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units fully vest on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units fully vest on April 1, 2017, the first day of the month following the date of satisfaction of certain performance criteria."}],"balance_after":1750,"derivative":{"underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001104659-17-020070","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917020070/a4.xml","form_type":"4"}},{"id":4404081,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-03-03T17:17:43.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":10782,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in 48 equal monthly installments beginning on April 1, 2017."}],"balance_after":10782,"derivative":{"exercise_price":178.95,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":10782},"source":{"system":"sec-edgar","filing":"0001104659-17-014111","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917014111/a4.xml","form_type":"4"}},{"id":4404080,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-03-03T17:17:43.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":5930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning on March 1, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning on March 1, 2018."}],"balance_after":5930,"derivative":{"underlying":"Common Stock","underlying_shares":5930},"source":{"system":"sec-edgar","filing":"0001104659-17-014111","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917014111/a4.xml","form_type":"4"}},{"id":4404079,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-03-03T17:17:43.000Z","date":"2017-03-01","kind":"exercise","acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on March 1, 2016 and vest in four equal annual installments beginning on March 1, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on March 1, 2016 and vest in four equal annual installments beginning on March 1, 2017."}],"balance_after":13125,"derivative":{"underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0001104659-17-014111","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917014111/a4.xml","form_type":"4"}},{"id":4404078,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-03-03T17:17:43.000Z","date":"2017-03-02","kind":"sale","acquired":false,"shares":1428,"price":177.61,"value":253627.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units."}],"balance_after":4772,"source":{"system":"sec-edgar","filing":"0001104659-17-014111","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917014111/a4.xml","form_type":"4"}},{"id":4404077,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-03-03T17:17:43.000Z","date":"2017-03-01","kind":"exercise","acquired":true,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6200,"source":{"system":"sec-edgar","filing":"0001104659-17-014111","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917014111/a4.xml","form_type":"4"}},{"id":4507868,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-03T18:35:40.000Z","date":"2017-01-03","kind":"sale","acquired":false,"shares":190,"price":136.26,"value":25889.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and was made in order to pay the tax liability arising from the vesting of restricted stock units."}],"source":{"system":"sec-edgar","filing":"0001104659-17-000315","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917000315/a4.xml","form_type":"4"}},{"id":4507867,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-03T18:35:40.000Z","date":"2017-01-01","kind":"grant","acquired":true,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the vesting of restricted stock units following satisfaction of certain performance criteria.  Each restricted stock unit represents the right to receive one share of common stock."}],"source":{"system":"sec-edgar","filing":"0001104659-17-000315","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465917000315/a4.xml","form_type":"4"}},{"id":4567795,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-11-03T18:27:04.000Z","date":"2016-11-02","kind":"sale","acquired":false,"shares":327,"price":121.29,"value":39661.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected in accordance with the terms of the underlying restricted stock unit award agreement and was made in order to pay the tax liability arising from the vesting of restricted stock units."}],"balance_after":1515,"source":{"system":"sec-edgar","filing":"0001104659-16-154687","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465916154687/a4.xml","form_type":"4"}},{"id":4567794,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-11-03T18:27:04.000Z","date":"2016-11-01","kind":"grant","acquired":true,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the vesting of restricted stock units following satisfaction of certain performance criteria.  Each restricted stock unit represents the the right to receive one share of common stock."}],"balance_after":1842,"source":{"system":"sec-edgar","filing":"0001104659-16-154687","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465916154687/a4.xml","form_type":"4"}},{"id":4596219,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2016-09-23T20:50:50.000Z","date":"2016-09-21","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On September 21, 2015, the reporting person was granted 5,000 restricted stock units, vesting in in four equal annual installments beginning September 21, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On September 21, 2015, the reporting person was granted 5,000 restricted stock units, vesting in in four equal annual installments beginning September 21, 2016."}],"balance_after":3750,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-16-146349","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465916146349/a4.xml","form_type":"4"}},{"id":4596218,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-09-23T20:50:50.000Z","date":"2016-09-22","kind":"sale","acquired":false,"shares":408,"price":108.12,"value":44112.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units."}],"balance_after":842,"source":{"system":"sec-edgar","filing":"0001104659-16-146349","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465916146349/a4.xml","form_type":"4"}},{"id":4596217,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":44725,"kind":"person","name":"Huber Martin H. Jr.","position":1,"cik":"0001653276","reported_name":"Huber Martin H. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-09-23T20:50:50.000Z","date":"2016-09-21","kind":"exercise","acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1250,"source":{"system":"sec-edgar","filing":"0001104659-16-146349","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465916146349/a4.xml","form_type":"4"}}]}